Bris­tol-My­ers Squibb brings Op­di­vo to a joint im­muno-on­col­o­gy pro­gram with Nek­tar’s new T cell am­pli­fi­er

Six years ago, when Steve Dober­stein took over as chief sci­en­tif­ic of­fi­cer at Nek­tar Ther­a­peu­tics, he set up a new bi­o­log­ics re­search group with an eye to ex­pand­ing on the biotech’s base of small mol­e­cules. The very first project they would un­der­take went on to be­come NK­TR-214, a pre­clin­i­cal bi­o­log­ic that the com­pa­ny be­lieves can play a role in im­muno-on­col­o­gy.

To­day, Nek­tar is pulling the wraps off a deal to col­lab­o­rate with Bris­tol-My­ers Squibbs’ I/O all­stars in R&D to see how their ex­per­i­men­tal drug match­es up with Op­di­vo, one of the lead­ers in the first wave of check­point in­hi­bi­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.